Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.97 |
| ▸ | NPC1 | O15118 | 13/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.97 |
| ▸ | GFER | P55789 | 4/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MIF | P14174 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 5/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325909 | 0.91 | RAB9A (0.83) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL13325938 | 0.89 | RAB9A (0.80) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL11029988 | 0.87 | RAB9A (0.74) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL13325735 | 0.86 | RAB9A (0.75) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL966793 | 0.85 | RAB9A (0.74) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL31154574 | 0.85 | RAB9A (0.74) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL29080554 | 0.85 | RAB9A (0.74) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL970334 | 0.84 | RAB9A (0.73) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL25343703 | 0.84 | RAB9A (0.72) | RAB9ANPC1KDM4EGFERPOLB | |
| SCHEMBL972536 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4EGFERPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812530-A | Method for preparing imidazole pyridine compound by catalyzing lignin and model compound by Pd/C bi-component system | 中国科学院大连化学物理研究所 | 2024-10-22 | — | — | CN | claimed |
| JP-60233074-A | — | — | None | — | — | JP | disclosed |
| CN-118812530-A | Method for preparing imidazole pyridine compound by catalyzing lignin and model compound by Pd/C bi-component system | 中国科学院大连化学物理研究所 | 2024-10-22 | — | — | CN | disclosed |
| EP-2042501-B1 | COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDIPHYSICS CO LTD (JP) | 2017-04-12 | — | — | EP | disclosed |
| EP-2604601-A1 | HETERO RING COMPOUND | Astellas Pharma Inc. (JP) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012133607-A1 | PYRAZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2012-10-04 | — | — | WO | disclosed |
| US-8277777-B2 | Compound having affinity for amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8277777-B2 | Compound having affinity for amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20100092387-A1 | Novel Compound Having Affinity For Amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100092387-A1 | Novel Compound Having Affinity For Amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2042501-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| JP-S60233074-A | IMIDAZO(1,2-A)PYRIDINE DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1985-11-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092387-A1 | Novel Compound Having Affinity For Amyloid | APP, SLC43A1, APBA1 | RAB9A 1232/4885NPC1 138/4885KDM4E 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.